Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LAVA Therapeutics NVLVTX · Entity 73047 | Chief Medical Officer | February 13, 2025 | February 19, 2025 |
| Prelude Therapeutics IncPRLD · Entity 5561 | Chief Medical Officer | May 01, 2026 | May 04, 2026 |
| Radius Health, Inc.RDUS · Entity 124173 | Chief Medical Officer | February 26, 2020 | February 28, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LAVA Therapeutics NV
Report date February 13, 2025 · Filed February 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.93 · Expires 2035-03-12 | Direct | 130,850 |
Reported balance
After 2025-02-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-02-13 · Grant · Acquired 130,850 · Balance 130,850 F1: The shares underlying the option vest in 48 equal monthly installments beginning on March 13, 2025, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option vest in 48 equal monthly installments beginning on March 13, 2025, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on each such vesting date.
Prelude Therapeutics Inc
Report date May 01, 2026 · Filed May 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.70 · Expires 2036-04-30 | Direct | 450,000 |
Reported balance
After 2026-05-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-01 · Grant · Acquired 450,000 · Balance 450,000 F1: The stock option vests as to 25% of the total shares on May 1, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as to 25% of the total shares on May 1, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Radius Health, Inc.
Report date February 26, 2020 · Filed February 28, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,744 |
Reported balance
After 2020-02-26 transaction · row 1
1 source rowRow 1 · 2020-02-26 · Sale · Disposed 1,256 · Balance 33,744 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2026 Filed May 4, 2026 20:10 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantEmployee Stock Option (right to buy) · Derivative | 450,000 | $4.70 Strike: $4.70 | $2,115,000.00 |
DisclosureSEC source: 0001489966-26-000004 · primarydocument.xml · derivative · entry 1 Morris Charles Q · CIK 0001489966 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2036-04-30 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on May 1, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 01:15 UTC | LAVA Therapeutics NV LVTX · Entity 73047 | GrantShare Options (Right to Buy) · Derivative | 130,850 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0001415889-25-004525 · form4-02182025_080205.xml · derivative · entry 1 Morris Charles Q · CIK 0001489966 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,850 Underlying: Common Shares · 130,850 shares Expires 2035-03-12 F1 · derivative.exercise_date: The shares underlying the option vest in 48 equal monthly installments beginning on March 13, 2025, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on each such vesting date. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 21:15 UTC | Radius Health, Inc. RDUS · Entity 124173 | SaleCommon Stock | 1,256 | $17.93 | $22,523.85 |
DisclosureSEC source: 0001209191-20-013793 · doc4.xml · nonDerivative · entry 1 Morris Charles Q · CIK 0001489966 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,744 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 23:00 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $19.96 | $0.00 |
DisclosureSEC source: 0001209191-20-012155 · doc4.xml · derivative · entry 2 Morris Charles Q · CIK 0001489966 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-02-20 F2 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on February 20, 2021, and the remaining shares shall vest in substantially equal monthly installments over the following three years, subject to continued service with RDUS through such dates. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 23:00 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantCommon Stock | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-012155 · doc4.xml · nonDerivative · entry 1 Morris Charles Q · CIK 0001489966 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 F1 · price: The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. The restricted stock units vest in three substantially equal annual installments on each of the first three anniversaries of the grant date of February 20, 2020, subject to continued service with RDUS through such dates. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 23:16 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $19.18 | $0.00 |
DisclosureSEC source: 0001209191-19-013718 · doc4.xml · derivative · entry 2 Morris Charles Q · CIK 0001489966 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2029-02-22 F2 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on February 22, 2020, and the remaining shares shall vest in substantially equal monthly installments over the following three years, subject to continued service with RDUS through such dates. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 23:16 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantCommon Stock | 15,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-013718 · doc4.xml · nonDerivative · entry 1 Morris Charles Q · CIK 0001489966 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · price: The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. The restricted stock units vest in four substantially equal annual installments on each of the first four anniversaries of the grant date of February 22, 2019, subject to continued service with RDUS through such dates. Read SEC document |
| September 04, 2018 Filed Sep 5, 2018 21:32 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantStock Option (Right to Buy) · Derivative | 130,000 | $0.00 Strike: $19.93 | $0.00 |
DisclosureSEC source: 0001209191-18-049624 · doc4.xml · derivative · entry 1 Morris Charles Q · CIK 0001489966 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2028-09-04 F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on September 4, 2019, and the remaining shares shall vest in substantially equal monthly installments over the following three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.